QLT Inc. (QLTI) Announces Preliminary Findings From Phase II Clinical Trial Of Lemuteporfin-Injectable In BPH; Shares Dip 3% On Results
VANCOUVER, Feb. 14 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI - News; TSX: QLT - News) today announced that a Phase II clinical trial of lemuteporfin- injectable in patients with benign prostatic hyperplasia (BPH) did not meet the study's primary efficacy objective at three months. While the decrease in AUA (American Urological Association) Symptom Score was consistent with that seen after other minimally invasive therapies there was no significant difference between treatment and sham-control groups.
"The preliminary result of this trial does not support initiation of Phase III clinical trials of lemuteporfin in BPH at this time," commented Bob Butchofsky, QLT's acting Chief Executive Officer. "We intend to complete the analysis of the data, including the six-month measurements, in order to determine the best path forward."
QLT will discuss these results on Wednesday, February 22, 2006, at 8:30 a.m. ET (5:30 a.m. PT) during its previously scheduled investor conference call to discuss year-end results and 2006 guidance. The call will be broadcast live via the Internet at www.qltinc.com. To participate on the call, please dial 1-800-525-6384 (North America) or 780-409-1668 (International) before 8:30 a.m. ET. A replay of the call will be available via the Internet and also via telephone at 1-800-695-1018 (North America) or 402-220-1753 (International), access code 9614255.
QLT is a global biopharmaceutical company specializing in developing treatments for eye diseases as well as dermatological and urological conditions. We have combined our expertise in the discovery, development and commercialization of innovative drug therapies with our two unique technology platforms, photodynamic therapy and Atrigel®, to create products such as Visudyne® and Eligard®. For more information, visit our web site at www.qltinc.com.
QLT Inc.: |
